Stevanato Group (87N) Stock Overview
Engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 87N from our risk checks.
87N Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Stevanato Group S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.60 |
| 52 Week High | US$23.60 |
| 52 Week Low | US$11.90 |
| Beta | 0.57 |
| 1 Month Change | -4.23% |
| 3 Month Change | -32.67% |
| 1 Year Change | -31.31% |
| 3 Year Change | -31.66% |
| 5 Year Change | n/a |
| Change since IPO | -17.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| 87N | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 0.7% | 0.4% | 0.8% |
| 1Y | -31.3% | -21.0% | 6.3% |
Return vs Industry: 87N underperformed the German Life Sciences industry which returned -17.2% over the past year.
Return vs Market: 87N underperformed the German Market which returned 7.5% over the past year.
Price Volatility
| 87N volatility | |
|---|---|
| 87N Average Weekly Movement | 7.1% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 14.6% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 87N has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 87N's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 5,521 | Franco Stevanato | www.stevanatogroup.com |
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass forming machines; and after-sales services, such as spare parts and maintenance services.
Stevanato Group S.p.A. Fundamentals Summary
| 87N fundamental statistics | |
|---|---|
| Market cap | €3.71b |
| Earnings (TTM) | €140.60m |
| Revenue (TTM) | €1.17b |
Is 87N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 87N income statement (TTM) | |
|---|---|
| Revenue | €1.17b |
| Cost of Revenue | €834.25m |
| Gross Profit | €336.14m |
| Other Expenses | €195.55m |
| Earnings | €140.60m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Mar 04, 2026
| Earnings per share (EPS) | 0.52 |
| Gross Margin | 28.72% |
| Net Profit Margin | 12.01% |
| Debt/Equity Ratio | 30.4% |
How did 87N perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/23 13:46 |
| End of Day Share Price | 2026/02/23 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Stevanato Group S.p.A. is covered by 18 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Curtis Moiles | BNP Paribas |
| Hugo Solvet | BNP Paribas |
| Michael Ryskin | BofA Global Research |